CRISPR Therapeutics Faces Diverging Investor Sentiment Following Insider Trades Recent insider trades at CRISPR Therapeutics, including CEO Samarth Kulkarni’s sale of 18,360 shares, have drawn attention. While some analysts maintain a "buy" rating, others are skeptical, citing challenges in market uptake for therapies. The stock currently has an average price target of $73.11, reflecting mixed expectations.45